Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1-HER3 signaling.
Würth R, Donato E, Michel LL, Saini M, Becker L, Cheytan T, Doncevic D, Messmer T, Gutjahr E, Weber R, Klein C, Alborzinia H, Yildiz U, Vogel V, Hlevnjak M, Kozyulina P, Neuberth SJ, Schwerd-Kleine P, Jakab S, Pfarr N, Angeles AK, Laut AK, Karpova D, Falcone M, Hardt O, Theek B, Wagner CV, Becker M, Wagner S, Haselmayr M, Schmitt A, Müller-Tidow C, Riethdorf S, Pantel K, Zapatka M, Sültmann H, Herrmann C, Thewes V, Lichter P, Schneeweiss A, Sprick MR, Trumpp A.
Würth R, et al. Among authors: becker m.
Nat Cancer. 2025 Jan 3. doi: 10.1038/s43018-024-00882-2. Online ahead of print.
Nat Cancer. 2025.
PMID: 39753722